


MEHANIL PLUS TABLETS (100 tab)
₹610.00
Indications:
Type 2 Diabetes Mellitus
Dosage:
1 to 2 tablets twice daily before food or as directed by the Physician
5 in stock
Vaidyaratnam Mehanil Plus Tablets are advanced Ayurvedic tablets formulated to support individuals in maintaining balanced blood sugar levels as part of a holistic wellness routine. Crafted with traditional herbs such as Karavella, Guduchi, Medhika, and Asana, this herbal formulation assists in promoting metabolic wellness and supporting overall vitality.
Designed as a supportive medicine for Type 2 diabetes wellness, Mehanil Plus helps encourage healthy glucose metabolism while also supporting digestive function. Rooted in classical Ayurvedic knowledge and prepared by Vaidyaratnam Oushadhasala, this formulation is often considered among the best ayurvedic medicine for diabetes by individuals seeking plant-based, time-tested support for long-term metabolic balance. Ideal for those looking to adopt a natural approach to their daily routine, Mehanil Plus offers dependable herbal support in managing energy and well-being.
Why Choose Mehanil Plus Tablets?
Herbal Formulation
Made with time-honored Ayurvedic ingredients such as Karavella, Guduchi, Medhika, and Asana, traditionally known for their role in supporting healthy blood sugar levels and metabolic balance.
Supports Metabolic Wellness
Helps promote balanced glucose metabolism and assists in maintaining digestive health and sustained energy, key considerations when choosing the best ayurvedic medicine for diabetes support.
Key Benefits
Supports Healthy Blood Sugar Levels
Helps maintain glucose balance as part of a consistent daily wellness routine.
Promotes Metabolic Function
Assists in supporting digestion and metabolism naturally through herbal synergy.
Rich in Antioxidants
Contains Ayurvedic herbs traditionally known to help combat oxidative stress and support overall cellular health.
Only logged in customers who have purchased this product may leave a review.





Reviews
There are no reviews yet.